Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Ted Okon, MBA, considers what can be done to encourage PBM transparency

Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs

Published: 20 April 2018

Recent Videos: COA Conference Coverage

video

Nicolas Ferreyros, on the influence of pharmacy benefit managers

Nicolas Ferreyros, Director of Communications, Community Oncology Alliance, considers the influence of pharmacy benefit managers on the lives of cancer ...

video

Ira Klein, MD, MBA, FACP, on embracing value-based oncology care

Dr. Klein, Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Systems Inc., on embracing value-based ...

video

Nicolas Ferreyros, on what oncologists should know about their federal policymakers

Nicolas Ferreyros, Director of Communications, Community Oncology Alliance, offers opinion on what medical oncologists and practice administrators should know about ...

video

Ira Klein, MD, MBA, FACP, provides perspective on the rising cost of cancer drugs

Dr. Klein, Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Systems Inc., provides perspective on ...

video

Nicolas Ferreyros, explains why oncologists should communicate with their local representatives

Nicolas Ferreyros, Director of Communications, Community Oncology Alliance, explains why oncologists should communicate with their local representatives

video

Ira Klein, MD, MBA, FACP, on the role of value in cancer drug development

Dr. Klein, Senior Director, Healthcare Quality Strategy, Strategic Customer Group, Johnson & Johnson Health Care Systems Inc., how value plays ...

video

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

Dr. Johnson, Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute, shares her thoughts on biomarker development in managing ...

video

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

Dr. Johnson, Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute, tells us about some of the exciting new ...

video

Anshu Jain, MD, tells us what physicians & payers should know about proton therapy

Dr. Jain, Radiation Oncologist, COA Board Member, tells us what physicians and payers should know about proton therapy

video

Melissa Johnson, MD, on the updated NCCN guidelines in regards to PD-L1 testing

Dr. Johnson, Associate Director, Lung Cancer Research Program, Sarah Cannon Research Institute, elaborates on the recent updates to NCCN guidelines ...

Related Videos

video-image

Nicolas Ferreyros, on the influence of pharmacy benefit managers

video-image

Ira Klein, MD, MBA, FACP, on embracing value-based oncology care

video-image

Nicolas Ferreyros, on what oncologists should know about their federal policymakers

video-image

Ira Klein, MD, MBA, FACP, provides perspective on the rising cost of cancer drugs

video-image

Nicolas Ferreyros, explains why oncologists should communicate with their local representatives

video-image

Ira Klein, MD, MBA, FACP, on the role of value in cancer drug development

video-image

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

video-image

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

video-image

Anshu Jain, MD, tells us what physicians & payers should know about proton therapy

video-image

Melissa Johnson, MD, on the updated NCCN guidelines in regards to PD-L1 testing

video-image

Anshu Jain, MD, on the current controversy regarding proton therapy in cancer care

video-image

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

video-image

Anshu Jain, MD, explains why proton therapy is important in terms of delivery & outcomes

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares how COA is supporting Dayton Physicians Network

video-image

Matthew Hall, MD, tells us what physicians & payers should know about proton therapy

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares key takeaways from the 2019 COA Annual Conference

video-image

Matthew Hall, MD, considers whether the application of proton therapy is growing

video-image

Lakshmi Aggarwal, MD, explains why transparency is necessary in the healthcare system

video-image

Matthew Hall, MD, on the difference between photon therapy & proton therapy

video-image

Lakshmi Aggarwal, MD, considers the role of politics in oncology

video-image

Lucio Gordan, MD, shares how the shift in site of care is impacting community oncology

video-image

Lakshmi Aggarwal, MD, offers opinion on the evolving landscape of oncology

video-image

Lucio Gordan, MD, explains how practices should leverage their OCM performance data

video-image

Jesse Dresser evaluates the impact of payer trends on drug manufacturers' market access strategy

video-image

Lucio Gordan, MD, on best practices in delivering value-based care

video-image

Jesse Dresser shares what legal tools are available to dispensing oncology practices & pharmacies

video-image

Lucio Gordan, MD, describes the primary drivers of the cost of cancer care

video-image

Jesse Dresser considers the challenges for dispensing oncology practices regarding payer networks

video-image

Kathy Gaughran explains how Healthcare Success is helping community oncologists

video-image

Jesse Dresser on the trends he is observing between payers and dispensing practices & pharmacies

video-image

Bobbi Buell, MBA, regarding the biggest changes & challenges in oncology reimbursement in 2019

video-image

Sibel Blau, MD, on the pros & cons associated with participation in a clinically integrated network

video-image

Sean Brusky explains how the pharmaceutical industry is working to help community oncology

video-image

Sibel Blau, MD, elaborates on clinically integrated networks

video-image

Sean Brusky provides Genentech’s perspective on the rising cost of cancer drugs and patient access

video-image

Sibel Blau, MD, tells us more about IQ Oncology

video-image

Sean Brusky on taking value into consideration when developing cancer drugs

video-image

Sibel Blau, MD, shares what the QCCAN is doing for participating members

video-image

Michael Diaz, MD, on how community oncology is shaping the future of cancer care

video-image

Michael Diaz, MD, regarding high priority policy initiatives for COA

video-image

Michael Diaz, MD, articulates his goals for the coming year as president of COA

video-image

Michael Diaz, MD, shares exciting updates from the 2019 Community Oncology Conference

video-image

Stephen Schleicher, MD, MBA, regarding participation in a two-sided risk model

video-image

Stephen Schleicher, MD, MBA, discusses participation in the Oncology Care Model

video-image

Stephen Schleicher, MD, MBA, on the challenges associated with value-based care

video-image

James Hamrick, MD, on how practicing oncologists and the FDA could utilize real world evidence

video-image

James Hamrick, MD, explains how real world evidence figures into clinical trial design

video-image

James Hamrick, MD, discusses the value of real world evidence data

video-image

Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care

video-image

Ricky Newton on how COA has helped practices keep their in-office dispensing in network

video-image

Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices